

The Expanding Toolbox: Key Updates for ADCs in Lung Cancer



Monday, 8 August 2022 | 13:30-14:30 CET
Strauss 3, Messe Wien Exhibition & Congress Center
Wien, Austria

Objectives

- Review arising molecular markers in lung cancer
- Introduce ADC technology and its potential use in lung cancer
- Review current data for ADCs in NSCLC/SCLC and discuss how ADCs may be integrated into the NSCLC/SCLC treatment landscape

Faculty

Michael Thomas, MD

Thoraxklinik Heidelberg
gGmbH Universitätsklinikum
Heidelberg
Heidelberg, Germany



Tony Mok, MD

The Chinese University of
Hong Kong
Hong Kong



Charles Rudin, MD, PhD

Memorial Sloan Kettering
Cancer Center
New York, NY, USA



Agenda

13:30-13:35	Introduction	Michael Thomas, MD
13:35-13:55	Emerging Targets for Therapeutic Strategies in Lung Cancer	Michael Thomas, MD
13:55-14:15	Key Data Releases for ADCs in NSCLC	Tony Mok, MD
14:15-14:25	Implications of Current ADC Data for SCLC	Charles Rudin, MD, PhD
14:25-14:30	Q&A Session	Faculty Panel